Home > Insider Trading > Filing (0000899243-21-028984)

Filing Details

Accession Number:: 0000899243-21-028984
Form Type:: 4/A
Zero Holdings:: No
Publication Time:: 2021-07-20 16:17:27
Reporting Period:: 2021-07-13

Accepted Time:: 2021-07-20 16:17:27
Original Submission Date:: 2021-07-15
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1761612	Bicycle Therapeutics Plc	BCYC	()	4/A

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1185040	Kate Bingham	C/O Bicycle Therapeutics B900, Babraham Research Campus Cambridge X0 CB22 3AT		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Ordinary Shares	Disposition	2021-07-13	588	$33.50	1,875,049	No	4	S	Indirect	By SV Life Sciences Fund V, L.P.
Ordinary Shares	Disposition	2021-07-14	43,378	$34.01	1,831,671	No	4	S	Indirect	By SV Life Sciences Fund V, L.P.
Ordinary Shares	Disposition	2021-07-13	12	$33.50	39,625	No	4	S	Indirect	By SV Life Sciences Fund V Strategic Partners, L.P.
Ordinary Shares	Disposition	2021-07-14	917	$34.01	38,708	No	4	S	Indirect	By SV Life Sciences Fund V Strategic Partners, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By SV Life Sciences Fund V, L.P.
No	4	S	Indirect	By SV Life Sciences Fund V, L.P.
No	4	S	Indirect	By SV Life Sciences Fund V Strategic Partners, L.P.
No	4	S	Indirect	By SV Life Sciences Fund V Strategic Partners, L.P.

Footnotes

These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein.
These shares were sold by SVLS V LP pursuant to its Rule 10b5-1 Plan enacted prior to the date of the sale disclosed herein.
These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein.
These shares were sold by SVLS V SPP pursuant to its Rule 10b5-1 Plan enacted prior to the date of the sale disclosed herein.